Brief: Immunocore Announces Randomization Of First Patient In The Global, Registrational Phase 3 Clinical Trial Testing brenetafusp For The Treatment Of First-Line Advanced Or Metastatic Cutaneous Melanoma

Immunocore Holdings

18/06/2024 12:17

June 18 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE
GLOBAL, REGISTRATIONAL PHASE 3 CLINICAL TRIAL TESTING
BRENETAFUSP FOR THE TREATMENT OF FIRST-LINE ADVANCED OR
METASTATIC CUTANEOUS MELANOMA

Source text for Eikon:  ID:nGNXPBZ0y 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))